T he renin-angiotensin system occupies a central role in blood pressure regulation. 1 The major effector peptide of the renin-angiotensin system, angiotensin II (Ang II), is generated by sequential cleavage of the substrate angiotensinogen and acts via the angiotensin type 1 (AT 1 ) receptor to increase blood pressure.
T he renin-angiotensin system occupies a central role in blood pressure regulation. 1 The major effector peptide of the renin-angiotensin system, angiotensin II (Ang II), is generated by sequential cleavage of the substrate angiotensinogen and acts via the angiotensin type 1 (AT 1 ) receptor to increase blood pressure. 2, 3 Studies from our laboratory using kidney cross-transplantation have demonstrated the critical role of AT 1 receptors inside the kidney to control blood pressure 4 and to promote hypertension. 5 In the kidney, AT 1 receptors are ubiquitously expressed in glomeruli, vascular and renal epithelia. 6 Ang II-dependent hypertension is associated with enhanced renal sodium reabsorption, suggesting that AT 1 receptors affect blood pressure through control of renal sodium handling. 3 Sodium is reabsorbed from the glomerular ultrafiltrate sequentially as it flows along the length of the nephron. A significant proportion (≈60%) of filtered sodium is normally reabsorbed by the proximal tubule, largely in iso-osmotic fashion. 7 On the other hand, only ≈5% of the filtered sodium load is reclaimed in the collecting duct, the terminal portion of the nephron. Despite the relatively small magnitude of sodium reabsorption by the collecting duct, it has been suggested that fine-tuning of sodium reabsorption by this most distal segment of the nephron represents a key step for the final regulation of sodium balance and blood pressure. 8 In the collecting duct, sodium transport is primarily mediated by the epithelial sodium channel (ENaC). 8 The capacity of this pathway to affect blood pressure is highlighted by observations that gain-of-function mutations of ENaC cause hypertension. 9 Although regulation of ENaC by aldosterone acting through the mineralocorticoid receptor has been well documented, 10 recent studies have suggested direct effects of angiotensin via the AT 1 receptor in the collecting duct to modulate sodium reabsorption. [11] [12] [13] [14] The collecting duct consists of 2 main epithelial cell lineages: principal and intercalated cells. 15 The traditional view is that principal cells play the predominant role in reabsorption of water and sodium, whereas intercalated cells are primarily responsible for urinary acidification, with limited cross talk because of the lack of gap junctions between the 2 cell types. 16, 17 On the contrary, recent work has shown substantive sodium reabsorption by intercalated 2
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June 2016 cells, 18 along with coordinated actions of the 2 collecting duct cell lineages by paracrine mediators. 19, 20 The goal of this study is to examine the contribution of direct actions of AT 1A receptors in principal cells of the collecting duct to blood pressure homeostasis and hypertension pathogenesis. To this end, we used Cre-loxP techniques to specifically eliminate AT 1A receptors from principal cells. We found that AT 1A receptors in principal cells of the collecting duct have little influence on basal blood pressure or adaptation to changes in dietary salt intake, whereas they contribute modestly to the initiation phase of Ang II-induced hypertension, associated with sodium retention and regulation of αENaC protein abundance.
Material and Methods

Study Approval
All experimental mice, maintained on a 129/SvEv background, were bred in an Association for Assessment and Accreditation of Laboratory Animal Care International-accredited animal facility at the Durham Veterans Affairs Medical Center under National Institutes of Health Guidelines for Care and Use of Laboratory Animals and housed with free access to standard rodent chow and water unless otherwise specified.
Statistical Analysis
The values for each parameter within a group are expressed as the mean±SEM. For comparisons between 2 experimental groups with normally distributed data, statistical significance was assessed using unpaired t test. For comparisons within groups, a paired t test was used. Normality was determined using the Shapiro-Wilk W test. P<0.05 was considered statistically significant.
Detailed description of procedures is available in Methods in the online-only Data Supplement.
Results
Generation of Mice Lacking AT 1A Receptor in Principal Cells of Collecting Duct
To delete the floxed Agtr1a allele only in the principal cells of the collecting duct, we used the transgenic mouse line where Cre expression is driven by the promoter of the human AQP2 gene. 21 Specific expression of Cre in principal cells was verified by crossing with a double-fluorescence reporter mouse (mTmG), the presence of Cre recombinase triggers green fluorescence protein expression on a background of constitutive expression of red florescence. As shown in Figure 1 , robust Cre recombinase activity was restricted to principal cells of the collecting duct. We performed a series of crosses to generate AQP2-Cre-Agtr1a flox/flox mice lacking AT 1A receptors in principal cells (PCKO) on 129/SvEv background. To verify the extent of AT 1A receptor deletion in PCKO mice, we prepared purified preparations of enriched inner medullary collecting ducts. Using real-time reverse transcription polymerase chain reaction, we found a significant ≈60% reduction in AT 1A receptor mRNA in PCKO inner medullary collecting ducts compared with controls (1±0.2 versus 0.39±0.05; P=0.04). We suggest that the residual AT 1A R mRNA receptor expression in these inner medullary collecting ducts is primarily because of AT 1A receptor expression in intercalated cells, which we have found to express significant levels of AT 1A receptors (Stegbauer et al, submitted) . To determine whether deletion of AT 1A receptors from principal cells might affect expression in other parts of the kidney, we compared AT 1A receptor mRNA levels in kidney cortex of control and PCKO mice and found no significant differences (control: 1±0.3 versus PCKO: 0.85±0.2; P=0.72; Figure S1 in the online-only Data Supplement).
Absence of AT 1A Receptors Does Not Affect Baseline Blood Pressure or Sodium Sensitivity
To define the impact of deleting AT 1A receptors in principal cells on blood pressure, radiotelemetry units were implanted into 8-to 12-week-old male PCKO (n=6) and control mice (n=6) to measure intra-arterial pressures. Baseline blood pressures were similar in control and PCKO mice (122±2 versus 122±2 mm Hg; Figure 2 ). We also measured cortical renin mRNA levels at baseline and found no differences between control and PCKO mice (1±0.12 versus 0.82±0.08; P=0.23). Likewise, basal urinary sodium excretion was not In previous studies, we found that mice with global deficiency of AT 1A receptors have exaggerated sodium sensitivity, 22 defined as enhanced blood pressure fluctuation in response to alterations in dietary sodium intake. 23 As shown in Figure 2 , with 1-week of low-sodium (<0.02% NaCl) feeding, mean arterial pressure fell significantly in the 129/SvEv control mice from 122±1 mm Hg to 118±2 mm Hg (P=0.0056), which is characteristic of the 129/SvEv strain. A similar pattern was seen in the PCKO mice, where blood pressure fell 122±1 mm Hg to 117±1 mm Hg (P=0.0043), but blood pressures on low-salt diet were not different from controls (P=0.62). Similarly, with a high-sodium (6% NaCl) diet, there was a significant increase in mean arterial pressure in control mice compared with the normal-salt diet (132±1 mm Hg versus 122±1 mm Hg; P=0.0002). An equivalent increase was seen in the PCKOs during high-salt feeding, but once again, the blood pressures during high-salt feeding were not different between the groups (PCKO: 130±2 mm Hg; controls: 132±2 mm Hg; P=0.50). Thus, elimination of AT 1A receptor from principal cells does not affect baseline blood pressures and does not recapitulate the exaggerated sodium sensitivity seen in mice with global AT 1A receptor deficiency.
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Effects of AT 1A Receptor in Principal Cells on the Development of Hypertension
To determine the contribution of AT 1A receptors in principal cell epithelia to the development of hypertension, osmotic minipumps were implanted into PCKO mice and controls to infuse Ang II for 2 weeks and intra-arterial pressures were measured by radiotelemetry. As shown in Figure 3A , during the initial phase of hypertension (days 2-8), there was a modest but significant attenuation of mean arterial pressure in the PCKOs (163±6 mm Hg) compared with controls (178±2 mm Hg; P<0.05; by 1-way ANOVA). Similarly, as shown in Figure 3B , mean arterial pressure averaged during the first 9 days of Ang II infusion was significantly attenuated in the PCKO mice (t test, *P<0.05). However, after day 10 of Ang II infusion, blood pressure levels were virtually identical between groups and there was no difference in blood pressures in this later phase of hypertension. To assess cardiac hypertrophy, an important clinical sign of end-organ damage in hypertension, we measured heart-to-body weight ratios. In mice that did not receive Ang II, heart:body weight ratios were similar in controls (4.94±0.2 mg HW/g BW) and PCKOs (5.02±0.3 mg/g; P=0.81). As shown in Figure 4 , heart:body weight ratios were higher in both groups after Ang II infusion for 14 days compared with noninfused mice (PCKO: P=0.0055; controls: P=0.0004), but although the extent of cardiac hypertrophy induced by Ang II tended to be less in the PCKOs, this difference was not statistically significant (PCKO: 7.08±0.3 mg/g; controls: 7.6±0.4 mg HW/g BW; P=0.36).
To determine whether modification of other vasoactive systems regulated by Ang II might be affected in the PCKOs, we measured expression of inducible cyclo-oxygenase isoform, COX2. We found no differences in COX2 mRNA expression in renal medulla between PCKO and controls after 2 weeks of Ang II infusion (control: 1±0.4 versus PCKO: 0.75±0.2; P=0.55; Figure S2A ). We also examined urinary prostaglandin PGE 2 excretion in the experimental groups ( Figure S2B ). We found no difference in urinary PGE 2 excretion at baseline (control: 466±42 pg/24 h versus PCKO: 461±38 pg/24 h; P=0.92). After 2 weeks of Ang II infusion, urinary PGE 2 levels increased significantly and to a similar extent in both groups (PCKO: 1482±245 pg/24 h, #P=0.01 versus baseline; controls: 1330±141 pg/24 h; *P=0.0017 versus baseline).
Exaggerated Natriuresis in PCKO Mice
To investigate the early separation in blood pressures between PCKO and control mice, we performed a sodium balance study. A separate group of mice were individually placed in specially designed metabolic cages 24 with access to 10 g/d gel diet containing nutrients, water, and 0.1% wt/wt sodium (Nutra-Gel; Bio-Serv, Frenchtown, NJ). After 5 days of baseline collections, the mice were implanted with osmotic minipumps infusing Ang II as described above. Urinary sodium content was determined using an IL943 Automatic Flame photometer per manufacturer's instructions (Instrumentation Laboratory, Lexington, MA). After 7 days of Ang II infusion, urinary sodium excretion was significantly higher in the 
Modulation of ENaC Protein Abundance by AT 1A Receptors in Principal Cells of the Collecting Duct
Previous studies have suggested that direct actions of Ang II on AT 1 receptors in the collecting duct can affect blood pressure by directly stimulating the activity of the ENaCs. 25 Accordingly, to determine whether the absence of AT 1A receptors in the principal cells of the collecting duct affected the abundance of the αENaC subunit, we measured αENaC protein by immunoblotting. The anti-αENaC antibody used in this study typically recognizes specific protein bands in kidney with apparent masses of ≈85 and ≈40 kDa. 26, 27 Previous work has suggested that the ≈85-kDa form is the full-length form, whereas the smaller ≈40-kDa band is a proteolytic fragment of the α-subunit [27] [28] [29] [30] cleaved near the NH 2 terminus. 31 This proteolytic cleavage enhances activity of the channel.
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Because ENaC is expressed in both connecting tubule and collecting duct in the cortex and expression of the AQP2-Cre is more robust in the renal medulla, we focused on ENaC levels in medulla. As shown in Figure 5A , relatively low levels of the full-length and cleaved forms of αENaC protein were detected at baseline in both control and PCKO mice and there were no significant differences in total αENaC protein abundance between the groups. These data indicate that, under basal conditions, the AT 1 receptor has little influence on abundance of αENaC protein in medullary collecting duct. This is consistent with our finding of similar blood pressures at baseline in control and PCKO mice. Infusion of Ang II for 7 days caused a significant increase in medullary full-length αENaC protein abundance in control mice (basal: 0.77±0.1 versus Ang II: 1.88±0.4; P=0.03), but had no effect on medullary full-length αENaC protein abundance in PCKO mice (basal: 1.0±0.2 versus Ang II: 0.68±0.2; P=0.36). As shown in Figure 5B , after Ang II infusion, levels of both full length (0.40±0.1 versus 1±0.1; P=0.004) and cleaved αENaC (0.52±0.1 versus 1±0.2; P<0.05) were significantly reduced in PCKOs than in controls.
Urinary Aldosterone and Prostaglandin Metabolite Levels Are Similar in Ang II-Infused PCKO and Control Mice
To rule out the possibility that the observed differences in αENaC abundance might be related to alterations in Figure 4 . Mean heart:body weight (HW:BW) ratio before and after 2 wk of chronic angiotensin II (Ang II) infusions. Basal mean heart:body weight ratio is similar between control and PCKO mice. After 2 wk of Ang II infusion, both PCKO and control mice exhibited significant cardiac hypertrophy compared with baseline (δP=0.005 and *P=0.0004, respectively, vs baseline), but there were no differences in the extent of cardiac hypertrophy between groups. Values are mean±SEM. aldosterone levels, we compared urinary aldosterone excretion in control and PCKO mice at baseline and after 7 days of Ang II infusion. As shown in Figure 6 , Ang II infusion caused significant increases in aldosterone levels in both controls and PCKOs. However, there were no significant differences in levels of urinary aldosterone between the 2 groups either at baseline (PCKO: 3347±340 pg/24 h versus WT: 2792±334 pg/24 h; P=0. 26 
Discussion
Control of sodium excretion by the kidney is a key pathway for regulating body fluid volume and blood pressure. Guyton and associates have suggested that pressure-natriuresis mechanisms where rise in blood pressure triggers enhanced sodium excretion by the kidney provides a powerful compensatory system to prevent hypertension. 33 Accordingly, impairment of these pathways would be a prerequisite for sustained elevations in arterial pressure. However, recent work has suggested significant complexity in sodium handling, including immunologically modulated storage of excess sodium in the skin. 34 Nonetheless, substantial experimental and clinical evidence supports a key contribution of renal excretory mechanisms to blood pressure regulation, including kidney cross-transplantation experiments demonstrating the importance of the kidney as a mediator of hypertension, 5, 35 human genetic studies demonstrating capacity of mutations affecting renal epithelial transporters to cause chronic high or low blood pressure 9 and clinical studies documenting the efficacy of diuretics in treatment of hypertension. 36 The renin-angiotensin system is a major determinant of sodium homeostasis and its actions to affect blood pressure are primarily mediated by AT 1 receptors. 3 Our previous studies using kidney cross-transplantation showed that AT 1A receptors within the kidney are crucial for regulation of blood pressure 4 and for the development of hypertension. 5 Within the kidney, AT 1 receptors are broadly expressed by epithelial cells across the nephron where they have been shown to have potent influence on sodium reabsorption. 3 Among the various nephron segments, actions of AT 1 receptors in proximal tubule have perhaps been most clearly characterized. 37 In this regard, we have previously shown that cell-specific deletion of AT 1A receptors from epithelia of the proximal tubule is associated with reduced baseline blood pressure and substantial resistance to hypertension. 38 These effects are associated with reduced tubule fluid reabsorption, decreased abundance of key sodium transporters, and enhanced natriuresis. 38 However, elimination of AT 1A receptors from proximal tubule does not completely recapitulate the extent of blood pressure reduction or sodium sensitivity seen in the complete absence of renal AT 1A receptors, 2,5 indicating a significant contribution of other intrarenal AT 1A receptors. Accordingly, we examined the role of AT 1A receptors in collecting duct using cell-specific gene targeting.
In the classic view, aldosterone is considered to be the major regulator of sodium transport in the collecting duct through its actions to regulate the expression and activity of the ENaC. 39 Yet, mineralocorticoid receptor blockade by spironolactone has minimal effects to reduce blood pressure in Ang II-dependent hypertension, 40 and previous studies in isolated tubule preparations have demonstrated significant capacity for direct actions of Ang II to influence sodium reabsorption by the collecting duct. 11, 12, 14 Indeed, our current studies show that AT 1A receptors in the collecting duct affect sodium and blood pressure homeostasis. However, their impact on blood pressure is negligible at baseline. Instead, AT 1A receptors in principal cells seem to play a modest role during the initiation phase of Ang II-dependent hypertension, where they contribute to the exaggerated renal avidity for sodium, characteristic of this disorder. In the later phases of hypertension, this distinct contribution of AT 1A receptors in collecting duct wanes and blood pressures in PCKOs eventually reach elevated levels that are indistinguishable from controls. The AQP2-Cre transgene used in these studies is constitutively expressed, eliminating AT 1A receptors during embryonic development and allowing for the possibility of compensatory mechanisms potentially mitigating the physiological consequences of loss of these receptors from principal cells. Although we cannot detect compensatory changes such as changes in renin or aldosterone, or altered AT 1A receptor expression in other parts of the kidney, it is possible that a more dramatic phenotype might be observed using inducible gene deletion system in adult animals.
Our studies provide evidence for a physiological role of AT 1 receptors in the collecting duct in vivo, consistent with previous studies. For example, in an isolated perfused cortical collecting duct preparation, Peti-Peterdi et al 14 showed that luminal Ang II leads to an increase in ENaC activity through an AT 1 receptor-dependent mechanism. Moreover, mice completely lacking AT 1A receptors have reduced αENaC protein abundance despite an overall increase in circulating levels of aldosterone. 41 More recently, Mamenko et al, 12 using patch clamping in split-opened murine distal nephron showed that Ang II acting through AT 1 receptor stimulated ENaC by affecting channel gating, with similar findings in rat cortical collecting ducts.
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In this study, we demonstrate significant attenuation of expression of a key sodium channel, αENaC in the renal medulla of PCKOs during Ang II infusion. This reduced expression is observed with both the full-length and cleaved (activated) forms of the protein and is associated with the enhancement of natriuresis and diminished hypertension, despite high levels of aldosterone in PCKOs that are not different from controls. These differences in ENaC protein abundance can be attributed to direct actions of AT 1 receptors in principal cells based on the cell specificity of the genetic manipulation and equivalent aldosterone levels in PCKOs and controls. Our studies indicate that AT 1A receptors in principal cells constitute a significant regulatory pathway for ENaC in Ang II-dependent hypertension, consistent with previous work by Gonzalez and colleagues showing that enhancement of ENaC function by chronic Ang II infusion was not extinguished by an mineralocorticoid receptor inhibitor. 42 We have not specifically examined intracellular pathways linking AT 1 receptors to regulation of ENaC in principal cells, but previous studies have suggested that effects of Ang II on ENaC may be mediated via WNK kinases, 43 whereas aldosterone affects ENaC expression and activity through distinct pathways involving Sgk1. 44 Finally, although we have shown clear differences in ENaC protein levels between control and PCKOs during Ang II infusion, inhibitor studies with amiloride would be required to assess the impact of these differences in ENaC levels on natriuresis.
Perspectives
This study shows that although AT 1A receptors in the principal cells of the collecting duct have minimal influence on blood pressure or adaptation to changes in dietary salt intake, they play a modest role in the initiation of Ang IIdependent hypertension. In the presence of high ambient levels of Ang II, AT 1A receptors in the principal cells regulate αENaC protein abundance in the renal medulla and promote enhanced sodium reabsorption. In mice lacking AT 1A receptors in principal cells, there is a failure to upregulate αENaC protein in inner medulla, despite substantial elevations in aldosterone.
Sources of Funding
The authors' work in this area has been supported by funds from • Absence of angiotensin type 1A receptors in principal cells of the collecting duct has negligible effects on baseline blood pressure or responses to dietary salt intake, but modestly attenuates the initiation phase of angiotensin II-induced hypertension. This diminished hypertension is associated with reduced abundance of activated α epithelial sodium channel (ENaC) protein in the renal medulla.
What Is Relevant?
• We demonstrate that direct actions of AT 1 receptors on principal cells have effects on hypertension pathogenesis αENaC independent of aldosterone.
Summary
We describe for the first time the isolated physiological contributions of AT 1 receptor in principal cells in vivo during hypertension pathogenesis. Deletion of angiotensin type 1A receptors in principal cells of the collecting duct mice in mice (PCKO) have minimal influence on blood pressure or adaptation to changes in dietary salt intake. However, AT 1 receptors in principal cells play a role in the initiation phase of angiotensin II-dependent hypertension. This is associated with enhanced of natriuresis and reductions in activated or cleaved αENaC in the renal medulla in PCKO mice during angiotensin II-induced hypertension, despite high levels of aldosterone in PCKOs that are not different from controls. These differences in cleaved αENaC protein abundance can be attributed to direct actions of AT 1 receptors in principal cells. Our studies indicate that angiotensin type 1A receptors in principal cells constitute a significant regulatory pathway for activating ENaC in angiotensin IIdependent hypertension.
METHODS Mouse lines.
We utilized a mouse line with a conditional Agtr1a flox allele generated using homologous recombination in embryonic stem cells as described previously 1, 2 . To delete the AT1A receptor from the principal cells of the collecting duct, we utilized an inbred 129/SvEv transgenic mouse line expressing Cre recombinase specifically in principal cells of the collecting duct under the control of an AQP2 promoter (AQP2-Cre) 3 Isolated medullary collecting duct (IMCD) preparation. Suspensions enriched for inner medullary collecting duct (IMCD) segments were prepared as previously described 6 with slight modifications. Inner medullae were dissected from kidneys of 2 mice (4 kidneys pooled per sample) and then incubated in an enzymatic solution containing 0.2% collagenase (Sigma #C0130), 0.2% hyaluronidase (Sigma #H3884), and 100U/ml DNAse (Sigma #D5025) at 37°C for 40 mins at 650 mOsm/Kg with urea/NaCl, while agitating every 10 mins. The suspension was passed through 75µm mesh followed by 2 rinses, pelleting at 2500 rpms, and re-suspended in 350µl RLT buffer/β-ME followed by RNA extraction using the RNeasy Micro Kit (Qiagen).
Blood pressure measurements in conscious mice. Blood pressures were measured in conscious, unrestrained 8-12 week-old male PCKO (n=6) and control (n=6) mice using radiotelemetry as described previously 7 . Arterial blood pressure data were collected, stored, and analyzed using Dataquest A.R.T. software (Version 4.0, Data Sciences International, Saint Paul, MN). Blood pressures were measured, starting 7 days after catheter implantation to allow the mice to re-establish normal circadian rhythms 8 . Telemetry data were collected continuously with sampling every 5 min for 10-sec intervals. Baseline measurements were recorded for 7 consecutive days while mice were maintained on a normal diet (0.4% NaCl, Harlan Teklad). On day 8, mice were fed a low salt (<0.02% NaCl, Harlan Teklad) diet for one week. Mice were returned to normal sodium diet for at least 3 days before a high (6% NaCl, Harlan Teklad) salt diet was administered for one week. While on a normal salt diet, an osmotic minipump (Alzet, Cupertino, CA) infusing Ang II (Sigma, St. Louis, MO) at a rate of 1000ng/kg/min was implanted subcutaneously and blood pressure measurements were continued for 14 days.
RT-PCR for AT1A receptor and renin. RNA was isolated from IMCDs using an RNeasy Micro RNA purification kit (Qiagen, Germantown, MD). Reverse transcriptase was performed using qScript cDNA Supermix (Quanta Biosciences, Gaithersburg, MD) following manufacturer's instructions. SYBR Green-based quantitative PCR was carried out using the SYBR Green PCR Master Mix (AppliedBiosystems, Carlsbad, CA). Reactions were performed Values are mean ± SEM.
FIGURE S2B
S2B. At baseline, urinary prostaglandin metabolite (PGEM) levels were similar in controls and PCKOs. After 2 weeks of Ang II infusion, urinary PGEM levels increased significantly in both groups (# PCKO: P=0.01; *Controls: P=0.0017), but with Ang II infusion, there were no differences between controls and PCKOs. Values are mean ± SEM. 
